Purpose: To determine the correlation between therapeutic effects of IVA treatment on typical AMD (tAMD), and polypoidal choroidal vasculopathy (PCV) and the history of hypertension, diabetes mellitus, smoking history and single nucleotide polymorphisms (SNPs).
Introduction
The estimated prevalence of early Age-related Macular Degeneration (AMD) is reportedly 6.8% and that of late age-related macular degeneration 1.5% [1] . AMD is increasing due to the aging of the Japanese population [2] . Advanced age is the major risk factor for AMD, with more than 10% of the population older than 80 years having late AMD. By 2020, the number of people with AMD globally is expected to be around 200 million, thus posing a major public health challenge with substantial socioeconomic implications [3] . Systemic risk factors include cigarette smoking, obesity, sunlight exposure, and cardiovascular diseases. Cigarette smoking in particular is a strong and consistent risk factor for AMD. AMD patients are also at increased risk for cardiovascular disease and stroke. Several genetic loci have been associated with AMD, including two major loci in complement factor H (CFH) and ARMS2/HTRA1 [1] . In Asian populations, polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative AMD, while typical AMD (tAMD) is the typical subtype in Western populations. PCV was found to be present in 22.3% to 61.6% of wet AMD cases, suggesting the prevalence of PCV in Asians to be high [4] . Recognition of the key role played by vascular endothelial growth factor (VEGF) in CNV pathogenesis led to the development of VEGF inhibitors, a class of drugs that has since become firmly established as the standard of care [1] . VEGF inhibitors that have received approval in Japan include pegaptanib, ranibizumab, and aflibercept. According to another report, the choroidal thickness in eyes with typical AMD (tAMD) decreased significantly in response to intravitreal ranibizumab (IVR) or intravitreal aflibercept (IVA) treatment, as demonstrated at the 1-, 3-and 6-month examinations, while IVA-treated eyes showed further significant reductions in choroidal thickness as compared to those treated with ranibizumab [5] . A report on single nucleotide polymorphisms (SNPs) associated with AMD found that ARMS2/HTRA1 might be useful for predicting the requirement for additional treatment after 3 monthly injections of ranibizumab [6] . The genetic variants rs12614 (CFB), rs699947 (VEGFA) and rs7993418 (VEGFR1) were associated with a good response to ranibizumab, while rs12603486 and rs1136287 (SERPINF1) were associated with a poor response to this treatment [7] .
In this study, the effects of IVA treatment on tAMD and PCV were evaluated by following the course of best corrected visual acuity (BCVA), central retinal thickness (CRT), central corneal thickness (CCT) and their associations with hypertension, diabetes, smoking history, and SNPs (s10490924(ARMS2), rs800292(CFH), rs699947(VEGFA), rs1061170(CFH), rs13278062(TNF-RSF)).
Methods
Informed consent was obtained from each study participant in accordance with the protocol approved by the Human Studies Committee of Nihon University (Clinical trial.gov: NCT01824225). This investigation was performed according to the guidelines of the Declaration of Helsinki.
We enrolled untreated AMD patients who visited Nihon University Hospital from January 2013 to February 2014. All untreated AMD patients who came to the hospital underwent comprehensive ophthalmological examinations including fundus examination, fundus photography, OCT imaging, and fluorescence angiography, allowing the AMD type to be correctly diagnosed. We excluded cases not meeting the AMD diagnostic criteria and those lacking one year of followup. Ultimately, 125 patients (tAMD: 58 patients, PCV: 67 patients) were included in the study.
Blood samples were obtained from all patients and five SNPs (s 10490924 (ARMS 2), rs800292 (CFH), rs699947 (VEGFA), rs1061170 (CFH), rs13278062 (TNF-RSF)) were determined by the TaqMan method.
All patients were asked for hypertension and diabetes treatment histories and their smoking history. Smokers included those who had quit smoking before the study as well as current smokers. Statistical analyses were performed only for the presence of smoking history, i.e. the number of smokers and the smoking period were not added to the statistical analysis.
BCVA, CRT, and CCT were measured before the first treatment, after three monthly injections, and one year after starting treatment. CRT and CCT were measured by extended depth image OCT (EDI -OCT) using the Heidelberg Spectral is device.
Statistical analysis was carried out applying the t test and fisher's exact test for the variations of BCVA, CRT and CCT at 1 year in tAMD and PCV cases. We also conducted statistical analyses focusing on the changes at one year in BCVA, CRT and CCT, as well as the presence of hypertension, diabetes, and smoking history.
Statistical analyses were also conducted for the presence of hypertension, diabetes, and smoking history, and SNP mutation involvement in the presence of serous retinal detachment (SRD) and edema 3 months and 1 year after starting IVA treatment.
The analysis involved 58 eyes of tAMD patients and 67 eyes of PCV patients. Among the tAMD patients, there were 28 given bimonthly injections after three monthly injections and 30 who received pro re nata (PRN) injections after three monthly injections. Among the PCV patients, 33 were treated with bimonthly injections after three monthly injections and 34 received PRN injections after three monthly injections. Therefore, we evaluated tAMD and PCV in the bimonthly and PRN groups after three monthly injections, the standard methods of administering two IVA treatments for these two disease types. The treatment courses were thereby evaluated in 4 groups. The presence of exudation on OCT images was evaluated. Exudation was judged to be present whether oozing was caused by SRD or cystoids macular edema. We studied images for the presence of exudation at 3 months and 1 year after the start of treatment and the relationships of exudation with hypertension, diabetes, and smoking history were examined.
Results
There was no significant difference in baseline BCVA, CRT or CCT values between the two groups at baseline.
Improvements of BCVA, CRT and CCT were observed in nearly all groups at 1 year after initial treatment, but the CCT improvement was not significant after only 2 monthly administrations for PCV ( Table 1) .
The relationships between one-year changes in BCVA, CRT, and CCT in each group, with history of hypertension, diabetes and smoking were examined. In the tAMD group, the one-year change in CRT indicated a significant improvement in nonsmokers as compared to smokers. In the PCV group, the one-year change in CRT indicated a significant improvement in non-diabetic as compared to diabetic patients. No other significant associations were detected (Table 2) . Table 3 shows the relationships of hypertension, diabetes, and smoking history with treatment responses in the tAMD and PCV patients, divided into 4 groups according to the presence or absence of exudation at 3 months and 12months. In the tAMD group, significantly more patients with smoking history had exudation at both 3 months and 12 months. (CFH), and rs13278062 (TNF-RSF) in the tAMD and PCV groups. Statistical analyses were performed to compare the proportions of those without exudation in each of the 4 groups, based on the exudation at 3 months and at 12 months. With respect to the CFH (rs 1061170) mutation of tAMD, in the case with TT type, significant residual exudation was noted at both 3 and 12 months.
Discussion
IVA treatment for tAMD and PCV achieved good results in terms of BCVA, CRT and CCT improvements, as reported previously [8, 9] . A prior report described a significant difference in treatment effects between bimonthly injections and PRN injections, but we found no differences between these treatment methods in the present study [10] .
Our results differing from those of prior investigations might be attributable to their having been no administration delay in this study, as injections at our hospital can be administered on a PRN basis the same day. Fixed treatment is characterized by a fixed interval between injections, such that in the event of exacerbation or a sudden change before the next scheduled dose, deterioration may occur due to a delay in treatment.
CCT was not significantly improved with only 2 monthly doses of PCV. This is thought to be attributable to the choroid being thicker than normal in eyes with PCV. In our hospital, a PRN regimen allows immediate treatment at the time of deterioration, while injections every 2 months do not allow deterioration between doses to be managed aggressively. Thus, choroidal improvement is not significant.
In the tAMD group, the one-year change in CRT was significantly better in nonsmokers than in smokers. This suggests that VEGF production from the RPE is promoted and that exudation is exacerbated, resulting in poor CRT improvement, as compared with nonsmokers. Patients with thin choroids reportedly had a higher prevalence of intra-subretinal fluid [12] .
As mentioned earlier, eyes with PCV have a thickened choroid as compared to those with tAMD. For this reason, tAMD is more influenced by subretinal fluid than PCV and smoking is associated with exacerbation of AMD. These factors account for the significant difference in choroidal thickness in tAMD.
In the PCV group, the one-year change in CRT indicated significant improvement in non-diabetic as compared to diabetic patients. Another study demonstrated an increase in VEGF production in murine models of retinal inflammation with diabetes as compared to those without diabetes [13] .
These experimental results support our observation that CRT improvement was minimal in PCV patients with diabetes mellitus. Further examination is required to examine the apparent lack of treatment efficacy for tAMD in diabetic as compared to non-diabetic patients. In the tAMD group, significantly more patients with than without a smoking history showed exudation at both 3 months and 1 year after the start of treatment were.
As mentioned above, VEGF production is increased in the RPE of smokers. Abundant exudation remaining at 3 months and 1 year after the start of treatment is considered to be the result of excessive VEGF in the RPE. This does not appear to occur in PCV, which in our view arises from mechanisms differing from those producing tAMD. With respect to the CFH (rs1061170) mutation of tAMD, in the case with TT type, significant residual exudation was recognized at both 3 and 12 months after the start of treatment.
The CFH (rs1061170) polymorphism is reportedly a risk factor for the onset of AMD. This study also raised the possibility of the CFH (rs1061170) polymorphism being associated with treatment resistance to aflibercept after the onset of AMD. However, as we had only one case with the TT type in this study, further investigation with more patients is necessary [14] . In our patients treated with aflibercept administered by vitreous injection for PCV, studies of the SNPs known to be associated with AMD yielded no results allowing the therapeutic effects to be predicted.
Conclusion
Regardless of whether injections were bimonthly or PRN, aflibercept was found to be an effective treatment for fort AMD and PCV. BCVA improvements, as well as reductions in CRT and CCT, were achieved. However, smoking history in tAMD patients appears to be associated with a diminished response to IVA treatment.
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